Burosumab: Opening Up A New Era of Targeted Therapy for X-linked Hypophosphatemic Rickets
Burosumab, sold under the trade name Crysvita, is a human monoclonal antibody drug approved in 2018 for the treatment of X-linked hypophosphatemia and tumour-induced osteomalacia.
Crysvita Burosumab is a fully human monoclonal antibody against fibroblast growth factor 23 (FGF23), which can bind to FGF23 and inhibit its biological activity, restore renal reabsorption of phosphate, and increase serum 1,25-dihydroxyvitamin D concentration.
Burosumab: Lighting Up New Hope for Bone Disease Patients
Crysvita Burosumab focuses on the treatment of specific rare diseases, which often involve complex pathological mechanisms and have long been a medical challenge.
X-linked hypophosphatemic rickets is a rare genetic disease in which patients experience a decrease in blood phosphorus levels due to excessive excretion of phosphate by the kidneys, leading to skeletal disorders.
Traditional treatment methods mainly rely on oral phosphate and active vitamin D, but the efficacy is limited and may cause side effects.
Crysvita, as the world’s first targeted therapy for XLH, directly acts on the pathological mechanisms of the disease, bringing new hope to patients.
Burosumab: Rewriting the Pattern of Rare Bone Disease Treatment
Taking hypophosphatemic rickets as an example, due to the disorder of phosphorus metabolism in the body, patients may experience abnormal bone development, short stature, skeletal deformities, and other problems that seriously affect their quality of life.
As they age, they may also develop a series of complications, causing great harm to their physical and mental health.
In the past, treatment options for such diseases were extremely limited, and patients often fell into a long and difficult path of seeking medical treatment.
The birth of Crysvita can be regarded as a “medical revolution”.
It specifically blocks pathogenic signaling pathways through precise targeting mechanisms, effectively regulating the levels of key substances in the body, and thus improving disease symptoms from the root.
Simply put, it is like a precision-guided missile that directly hits the “key points” of a disease, bringing more effective treatment effects to patients.
However, DengYue‘s efforts to increase the affordability of the medicine are critical to ensuring that more patients benefit from it. So please feel free to ask us to buy Crysvita Burosumab.
Information from DengYueMedicine, HongKong Drug Wholesale Distributor, offers this information as a guide, not a substitute for professional medical advice. Consult your doctor before any treatment.
